North Chicago, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells healthcare products.

The test – which Babylon says is being offered at cost and will use a kit developed by Abbott – can be taken at home but won’t give an immediate results as the sample needs to be sent for ...

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 ...

However, I’m a bit worried about the potential change that was hinted at in Episode 10 -- "Testing." In true Abbott Elementary fashion, “Testing” was full of shenanigans. Janine found ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

The ABBOTT PRISM system is intended for in vitro diagnostic use only. A high throughput, highly automated test system for blood screening: The ABBOTT PRISM is a fully automated, high-volume blood ...

Abbott also currently offers the FDA-cleared molecular Alinity M STI assay to detect and differentiate between Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma ...

Organic growth, excluding COVID-19 testing-related sales was 10.1%. Stifel analyst Rick Wise has a positive outlook on Abbott’s Q4 2024 results and its 2025 projections. He sees strong momentum ...

*Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April ...